ClinicalTrials.gg
CompletedNCT02392026Updated Aug 15, 2023

Safety and Tolerability of Metronidazole Gel 1.3%

A Phase 4 interventional study of Metronidazole Gel in Vaginosis, Bacterial, sponsored by Insud Pharma. Completed at 8 sites in United States. Open to female participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-08-15.

Sponsored by Insud Pharma · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing metronidazole in Vaginosis, Bacterial — 2 open to participants now, 2 under way, 1 of them phase 3. Metronidazole · Vaginosis, Bacterial.

Enrollment
15th of 21
60 · median 166
Started
2015
with 2 others
Phase 4
9 of 21
1 open now
Registered
13th of 21
by date
Lead sponsor
1 of 21
Insud Pharma

Among the 21 studies testing metronidazole in Vaginosis, Bacterial, this one is the 15th largest by enrollment, is one of 3 that started in 2015, is one of 9 in phase 4, and was the 13th registered.

Vaginosis, Bacterial

240 studies on the registry are indexed under Vaginosis, Bacterial; 39 are open to participants now.

Browse Vaginosis, Bacterial studies →

Open to participants now

2 of the 21 studies testing metronidazole in Vaginosis, Bacterial are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About metronidazole

Metronidazole: first FDA approval 1963 (FLAGYL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 23 Vaginosis, Bacterial studies recruiting now, 7 (30%) set no upper age limit and 16 (70%) stop at 75 or younger; 2 take children under 18; 9 take healthy volunteers.

This study: 12 Years to 17 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing metronidazole in Vaginosis, Bacterial, or all of them as a file.
02

Study summary

Multicenter, open-label study to evaluate safety and tolerability of Metronidazole Vaginal Gel in females 12 to \<18 years for the treatment of bacterial vaginosis.

Read the detailed description

A multicenter, open-label study to evaluate safety and tolerability of Metronidazole Vaginal Gel 1.3% when administered as a single dose in adolescent females (aged 12 to \<18 years) for the treatment of bacterial vaginosis.

03

Conditions studied

  • Vaginosis, Bacterial

Browse trials for

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written assent and parent/legal guardian and authorization to disclose protected health information.
  • Post-menarcheal, adolescent female, 12 to \<18 years of age at time of Screening/Baseline Visit (Day 1).
  • In good general health at Screening visit with no known medical conditions that, in the Investigator's opinion, may interfere with study participation.
  • Has negative urine pregnancy test result prior to study treatment initiation.
  • Has clinical diagnosis of bacterial vaginosis.
  • Agree to abstain from sexual intravaginal intercourse for study duration.
  • Willing to avoid alcohol ingestion for 24 hours after administration of test article.
  • Agree to refrain from use of intravaginal products for duration of study (e.g. lubricated condoms, tampons, diaphragms, spermicides, feminine deodorant sprays, douches). Intravaginal Uterine Device (IUD) use is acceptable as long as it has been in place for 30 days prior to study enrollment.
  • Willing and able to participate in study, make required visits to the study center, and comply with all study requirements including concomitant medication and other treatment restrictions.

Exclusion criteria

Exclusion Criteria:

  • Pregnant, lactating, or planning to become pregnant during study period.
  • Currently menstruating or anticipate onset of menses during first 9 days of the study.
  • Experience a medical event with 90 days of Screening/Baseline Visit (Day 1).
  • Evidence of other infectious causes of vulvovaginal infection or condition that in the Investigator's opinion would confound the interpretation of the study results.
  • Severe symptoms of dysuria and/or pruritus, burning or irritation in vulvovaginal area.
  • Received systemic or intravaginal antifungal, antibacterial or antiparasitic drugs within 14 days of Screening/Baseline visit (Day 1). Antiviral therapies (non-intravaginal) are acceptable.
  • Has taken disulfiram or systemic (oral or injected) within 14 days of Screening/Baseline Visit (Day 1).
  • Had sexual intravaginal intercourse within 24 hours of Screening/Baseline (Day 1).
  • Demonstrated previous to metronidazole, either orally or topically administered, or any form of parabens or benzyl alcohol.
  • Known primary or secondary immunodeficiency condition/syndrome.
  • Being treated or planning to be treated during the study period for cervical intraepithelial neoplasia (CIN) or cervical carcinoma.
  • Using anticoagulation therapy with Coumadin (warfarin).
  • Previously treated with test article under this protocol.
  • Participate in an experimental drug/device trial within the last 30 days before Screening/Baseline Visit (Day 1).
  • Is judged by the Investigator to be unsuitable for any reason.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Metronidazole Gel

    Metronidazole Vaginal Gel

    Drug: Metronidazole Gel

Interventions

  • Metronidazole Vaginal Gel 1.3% administered via applicator

    Also known as: Metro Gel

06

What researchers measure

Primary outcomes

  1. Number of subjects with treatment-emergent adverse events (AEs), serious AEs, treatment-related AEs and AEs leading to study discontinuation after Metronidazole Vaginal Gel is administered in post-menarcheal, adolescent females with bacterial vaginosis.

    No serious AEs reported during the completed study

    Time frame: up to 10 days

  2. A multicenter open label to evaluate safety and tolerability of metronidazole vaginal gel 1.3% for adolescents female subject with bacterial and vaginosis

    Metronidazole Vaginal Gel 1.3% is safe, well tolerated, and efficacious in treating vaginal discharge and odor in adolescent females aged 12 to \< 18 years with bacterial vaginosis. The safety and efficacy profiles in this study were consistent with the known safety and efficacy profiles for the adult population and no new safety concerns were identified.

    Time frame: up tp 10 days

Secondary outcomes

  1. Number of subjects reporting presence of daily vaginal discharge and/or odor following single dose administration of Metronidazole Vaginal Gel 1.3%assessment of the presence of vaginal discharge and odor following single dose administration.

    no order or smelling observed

    Time frame: up to 10 days

07

Study locations

8 sites
  • Allergan Research Site #318
    Long Beach, California 90806, United States
  • Allergan Research Site #324
    Paramount, California 90723, United States
  • Allergan Research Site #315
    Bardstown, Kentucky 40004, United States
  • Allergan Research Site #314
    New Orleans, Louisiana 70115, United States
  • Allergan Research Site #319
    Columbus, Ohio 43231, United States
  • Allergan Research Site #322
    Dayton, Ohio 45406, United States
  • Allergan Research Site #321
    Memphis, Tennessee 38104, United States
  • Allergan Research Site #316
    Irving, Texas 75062, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Oct 2016, 13 months.

Of 17 phase 4 interventional studies under Vaginosis, Bacterial, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 41. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2015
First posted
Mar 18, 2015
StartActual
Aug 12, 2015
Primary completionActual
Oct 5, 2016
CompletionActual
Oct 5, 2016
Results delay requested
Oct 19, 2017
Last update
Aug 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02392026
Lead sponsor
Insud Pharma
Collaborators
Allergan Sales, LLC
Responsible party
Sponsor
First posted
Mar 18, 2015
Start date
Aug 12, 2015
Primary completion
Oct 5, 2016
Completion
Oct 5, 2016
Last update
Aug 15, 2023

Study contacts

Gina Giannantoni-Ibelli, MS
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metronidazole

Start the discussion